培美替尼在国内哪里买的到？

Pemetinib (also known as pemetinib, English trade name: pemazyre) is an FGFR2 inhibitor, suitable for patients with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement. Cholangiocarcinoma is a rare cancer that forms in the bile ducts, the long, thin tubes that carry digestive bile from the liver to the gallbladder and small intestine. Cholangiocarcinoma is highly aggressive and has a poor prognosis, and at the time of diagnosis, most patients with cholangiocarcinoma have advanced disease, meaning the disease can no longer be treated with surgery. Systemic treatment options for advanced cholangiocarcinoma are extremely scarce. The objective response rate (ORR) of first-line standard chemotherapy is only 15-26%. Drug resistance often occurs, and there is no standard second-line treatment option. It is the first targeted drug for the treatment of cholangiocarcinoma. This targeted breakthrough therapy brings good news to patients with cholangiocarcinoma.

On April 17, 2020, the U.S. Food and Drug Administration accelerated the approval of pemetinib for marketing. Where can I buy pemetinib in the country? According to Medical Partner Travel, pemetinib has not yet been launched in my country. Pemetinib is currently in phase II clinical research in China to evaluate the efficacy and safety of subjects with cholangiocarcinoma. Patients cannot buy pemetinib in the country. Patients in need of medicine can currently only purchase pemetinib that is available overseas. If financial conditions permit, patients or their families can go abroad to purchase it. Patients who are inconvenient to go abroad can contact legal and professional overseas medical service companies in China to purchase pemetinib through direct mail and sign a guarantee contract, saving worry and effort.

It is a potent and selective oral inhibitor discovered and developed by Incyte targeting FGFR subtypes 1/2/3. In preclinical studies, it has been confirmed that the drug has selective pharmacological activity against tumor cells with FGFR gene mutations. In the United States, the FDA has previously granted pemetinib Breakthrough Drug Designation (BTD) and Orphan Drug Designation (ODD) for the treatment of cholangiocarcinoma. Incyte Corporation of the United States was founded in 1991. It is a pharmaceutical company specializing in the research of drugs for AIDS (anti-HIV virus), cancer and inflammatory diseases.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.